Shares of McKesson Corporation (NYSE:MCK – Get Free Report) have received an average rating of “Moderate Buy” from the nineteen ratings firms that are presently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $1,026.18.
A number of research firms have issued reports on MCK. Morgan Stanley set a $977.00 target price on McKesson in a research report on Tuesday, October 6th. TD Cowen upped their price target on McKesson from $1,006.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Thursday. Robert W. Baird set a $1,015.00 price objective on McKesson in a research report on Thursday, August 6th. Barclays raised their price objective on McKesson from $925.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th. Finally, Leerink Partners boosted their price objective on McKesson from $1,070.00 to $1,200.00 and gave the company an “outperform” rating in a research report on Thursday.
Read Our Latest Report on McKesson
McKesson Stock Performance
MCK stock opened at $1,060.79 on Monday. The firm’s 50 day moving average price is $938.13 and its 200-day moving average price is $868.12. McKesson has a one year low of $723.68 and a one year high of $1,121.50. The firm has a market cap of $123.68 billion, a PE ratio of 27.28, a PEG ratio of 1.99 and a beta of 0.27.
McKesson (NYSE:MCK – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, beating the consensus estimate of $10.72 by $0.96. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The business had revenue of $110.96 billion for the quarter, compared to the consensus estimate of $109.90 billion. During the same period last year, the business posted $9.86 EPS. The company’s revenue was up 7.5% on a year-over-year basis. Equities research analysts predict that McKesson will post 45.26 EPS for the current fiscal year.
McKesson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Tuesday, December 1st will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Tuesday, December 1st. McKesson’s payout ratio is 9.67%.
Insider Activity at McKesson
In related news, CAO B Jr sold 111 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total transaction of $98,950.95. Following the sale, the chief accounting officer directly owned 521 shares of the company’s stock, valued at approximately $464,445.45. This represents a 17.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley Lerman sold 301 shares of McKesson stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $892.33, for a total value of $268,591.33. The disclosure for this sale is available in the SEC filing. Insiders sold 2,462 shares of company stock worth $2,511,106 over the last three months. 0.06% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of MCK. BankPlus Trust Department lifted its stake in McKesson by 72.1% in the 3rd quarter. BankPlus Trust Department now owns 1,805 shares of the company’s stock worth $1,541,000 after purchasing an additional 756 shares in the last quarter. Aberdeen Group plc lifted its stake in shares of McKesson by 143.4% in the third quarter. Aberdeen Group plc now owns 296,426 shares of the company’s stock valued at $253,091,000 after buying an additional 174,642 shares during the period. Moors & Cabot Inc. boosted its position in shares of McKesson by 3.9% in the 3rd quarter. Moors & Cabot Inc. now owns 3,081 shares of the company’s stock worth $2,631,000 after purchasing an additional 115 shares during the last quarter. Money Concepts Capital Corp lifted its holdings in McKesson by 20.3% during the 3rd quarter. Money Concepts Capital Corp now owns 2,179 shares of the company’s stock valued at $1,860,000 after purchasing an additional 368 shares during the last quarter. Finally, Allworth Financial LP boosted its position in McKesson by 15.7% during the 3rd quarter. Allworth Financial LP now owns 6,359 shares of the company’s stock worth $5,429,000 after buying an additional 861 shares during the period. Hedge funds and other institutional investors own 85.07% of the company’s stock.
McKesson News Summary
Here are the key news stories impacting McKesson this week:
- Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
- Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
- Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
- Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution
McKesson Company Profile
McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.
The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.
Founded in 1833, McKesson serves customers primarily in the United States and Canada.
Read More
- Five stocks we like better than McKesson
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.
